Perrigo (NYSE:PRGO) Trading Down 5.7% – Should You Sell?

Perrigo Company plc (NYSE:PRGO) dropped 5.7% during trading on Friday . The company traded as low as $10.55 and last traded at $10.52. Approximately 996,090 shares changed hands during trading, a decline of 69% from the average daily volume of 3,202,232 shares. The stock had previously closed at $11.16.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Weiss Ratings raised shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $19.33.

Perrigo Trading Down 4.7%

The business has a 50 day simple moving average of $10.68 and a 200-day simple moving average of $11.93. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -0.81, a price-to-earnings-growth ratio of 1.21 and a beta of 0.51.

Perrigo (NYSE:PRGO) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The company had revenue of $841.80 million during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the prior year, the company posted $0.60 EPS. The company’s quarterly revenue was down 7.2% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, equities analysts predict that Perrigo Company plc will post 2.11 earnings per share for the current year.

Perrigo Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Friday, May 29th were issued a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 10.9%. The ex-dividend date was Friday, May 29th. Perrigo’s dividend payout ratio (DPR) is -8.85%.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. SG Americas Securities LLC raised its holdings in shares of Perrigo by 1,495.6% in the 4th quarter. SG Americas Securities LLC now owns 134,433 shares of the company’s stock worth $1,871,000 after purchasing an additional 126,008 shares during the period. Vanguard Group Inc. grew its holdings in shares of Perrigo by 7.9% during the 4th quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock worth $208,568,000 after purchasing an additional 1,101,154 shares during the period. Sound Income Strategies LLC increased its position in Perrigo by 58.6% during the 4th quarter. Sound Income Strategies LLC now owns 1,138,357 shares of the company’s stock worth $17,110,000 after purchasing an additional 420,626 shares in the last quarter. Thompson Siegel & Walmsley LLC raised its holdings in Perrigo by 28.4% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 4,658,601 shares of the company’s stock valued at $64,848,000 after buying an additional 1,029,770 shares during the period. Finally, Gamco Investors INC. ET AL raised its holdings in Perrigo by 26.0% in the fourth quarter. Gamco Investors INC. ET AL now owns 1,077,785 shares of the company’s stock valued at $15,003,000 after buying an additional 222,287 shares during the period. 95.91% of the stock is owned by hedge funds and other institutional investors.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.